Pharmaceutical Contract Manufacturing: World Market Outlook 2012-2022

NEW YORK, Oct. 1, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pharmaceutical Contract Manufacturing: World Market Outlook 2012-2022

http://www.reportlinker.com/p0629356/Pharmaceutical-Contract-Manufacturing-World-Market-Outlook-2012-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical

Report Details

Your guide to trends and revenue potential in outsourced pharma manufacturing

How does the future look for pharmaceutical contract manufacturing? Visiongain's report gives you sales predictions to 2022. You find data, trends, opportunities and commercial prospects.

That new study lets you assess forecasted revenues at overall world market, submarket, and national market level. You see how and why the contract manufacturing industry and market will grow, as we predict. 

In our investigation you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses, including discussions of regulatory and commercial developments. 

You receive 64 tables, 54 charts and two research interviews. The following sections highlight what you discover in the report.

Prospects for submarkets

In addition to analyses of the overall world market, you see revenue forecasting of six world-level submarkets to 2022:

• Active pharmaceutical ingredient (API) manufacturing services

• Generic API manufacturing services

• Highly potent API (HPAPI) manufacturing services

• Finished dosage form manufacturing services

• Solid dosage manufacturing services

• Injectable dosage manufacturing services.

The work also breaks the overall world market into leading national markets.

Prospects for leading countries

Developments worldwide will influence the market, especially fast-rising demand in emerging countries. Individual national markets offer differing opportunities for contract manufacturers and companies seeking to outsource work.

In our study you discover revenue forecasts to 2022 for one regional block and 12 national markets:

• EU

• US

• Japan

• Germany, France, UK, Italy and Spain (EU5)

• Brazil, Russia, India and China (BRIC nations)

• South Korea.

This decade, demand for manufacturing services will rise in all leading countries. Contract manufacturing organisations (CMOs) in India and China will experience rising demand for API and generic drug manufacturing.

Also, uptake of specialist manufacturing services will benefit national markets from 2012.

Revenue growth opportunities for pharma contract manufacturers

Where will CMOs find the best growth opportunities from 2012? Our report shows you developmental trends and possibilities:

• Through expansion and consolidation, contract manufacturers will be more able to form strategic partnerships with pharmaceutical companies, offering a "one-stop-shop" for drug development and manufacture.

• Entering new geographical markets will provide the advantage of proximity for CMOs, as well as allowing them to use regional expertise.

• Manufacturing drugs for clinical trials will allow CMOs with low capacity to compete in the market.

Discover how progress and pharmaceutical industry demands can change the sector. Our investigation explains, discussing issues.

Prominent issues affecting the contract manufacturing industry

Our study lets you assess trends and outlooks for market growth from 2012. As the report shows, many issues will affect contract manufacturers:

• Development of biologics for treating cancer and autoimmune diseases

• Potential for biosimilars in the US, the EU and Japan

• Increasing generic drug sales in developed markets as payers limit healthcare spending

• Rising generic drug sales in emerging markets from wider access to healthcare

• Targeted therapies and orphan indications giving opportunities and challenges.

You see discussions of technological, commercial and economic matters, with emphasis on organisations competing in the industry.

Discussions of leading companies and prospects for market growth

What will happen next? Demand for outsourced manufacturing will increase from drug developers of all sizes. Revenue growth for contract manufacturers will be strong from 2012 to 2022.

Overall world revenue for that market area will reach $47.6bn in 2012, our report forecasts. Rising incidence of diseases such as cancer, arthritis and diabetes will increase demand for complex drugs and biologics.

Our study discusses 20 leading CMOs, including Catalent, Lonza and Patheon. You discover recent developments and assess outlooks for the future. Also, you see our interviews with two third party manufacturers.

Supplying HPAPIs and providing complex manufacturing services improve prospects for market growth from this decade onwards.

Seven ways Pharmaceutical Contract Manufacturing: World Market Outlook 2012-2022 benefits you

In particular, then, our study gives you the following knowledge on pharmaceutical contract manufacturing:

• Forecasted revenues to 2022 for the overall world market and submarkets

• Market forecasting to 2022 for the US, Japan, the 5 leading EU countries, the BRIC group and South Korea

• Assessment of 20 leading companies - services, activities, recent performances and outlooks

• Review of the regulatory landscape for pharmaceutical manufacturing in leading countries

• Opinions on the sector, including our research interviews with industry participants

• Investigation of competition and opportunities influencing growth

• Discussion of external and internal trends affecting industry performance.

That work gives independent analyses from our primary and secondary research. You receive information unique to our report.

With our study, you find business intelligence to help you understand the future of that industry and market.

Ordering now lets you discover prospects for contract manufacturing

Visiongain's study is for everybody needing commercial analyses for outsourced pharma manufacturing. You find data, trends and predictions there. Please order that report now.

Visiongain is a trading partner with the US Federal Government

CCR Ref number: KD4R6 

Table of Contents

1. Executive Summary

1.1 Pharmaceutical Contract Manufacturing: World Market Review

1.2 Report Contents

1.3 Research and Analysis Methods

2. Pharmaceutical Contract Manufacturing: An Introduction

2.1 Outsourcing in the Pharmaceutical Industry

2.1.1 Reasons to Outsource

2.1.2 Benefits to Outsourcing

2.1.3 Challenges in Outsourcing

2.1.4 Strategic Outsourcing vs. Tactical Outsourcing

2.1.5 Virtual Companies

2.2 Contract Manufacturing Organisations (CMOs)

2.2.1 Manufacturing Services Offered

2.2.2 Biopharmaceutical Manufacturing

3. The Pharmaceutical Contract Manufacturing Market 2012-2022

3.1 The Pharmaceutical Contract Manufacturing Market in 2011

3.1.1 The Roles of Biologics and Small Molecule Drugs in the Market 2011

3.2 The Pharmaceutical Contract Manufacturing Market: Overall Revenue Forecast 2012-2022

3.2.1 Market Drivers 2012-2022

3.2.2 Market Restraints 2012-2022

3.3 The API Contract Manufacturing Submarket 2012-2022

3.3.1 The API Contract Manufacturing Submarket: Revenue Forecast 2012-2022

3.3.2 The Generic API Contract Manufacturing Submarket: Revenue Forecast 2012-2022

3.3.3 The HPAPI Contract Manufacturing Submarket: Revenue Forecast 2012-2022

3.3.3.1 Focus on Oncology

3.4 The Finished Dosage Form Submarket 2012-2022

3.4.1 The Finished Dosage Form Contract Manufacturing Submarket: Revenue Forecast 2012-2022

3.4.2 The Solid Dosage Form Contract Manufacturing Submarket: Revenue Forecast 2012-2022

3.4.3 The Injectable Dosage Form Contract Manufacturing Submarket: Revenue Forecast 2012-2022

4. Leading National Markets for Pharmaceutical Contract Manufacturing 2012-2022

4.1 Supply and Demand for Contract Manufacturing Services

4.2 The Pharmaceutical Contract Manufacturing Market: Regional Breakdown 2011

4.3 The Pharmaceutical Contract Manufacturing Market: Regional Forecast 2012-2022

4.4 The US

4.4.1 The US: CMO Revenues 2012-2022

4.5 The EU

4.5.1 The EU: CMO Revenues 2012-2022

4.5.2 Germany: CMO Revenues 20120-2022

4.5.3 France: CMO Revenues 2012-2022

4.5.4 Italy: CMO Revenues 2012-2022

4.5.5 Spain: CMO Revenues 2012-2022

4.5.6 The UK: CMO Revenues 2012-2022

4.6 Japan

4.6.1 Japan: CMO Revenues 2012-2022

4.7 Pharmaceutical Contract Manufacturing in Emerging Markets

4.7.1 Outsourcing to Emerging Markets

4.7.1.1 Outsourcing to India and China

4.7.2 Brazil: CMO Revenues 2012-2022

4.7.3 Russia: CMO Revenues 2012-2022

4.7.4 India: CMO Revenues 2012-2022

4.7.5 China: CMO Revenues 2012-2022

4.8 South Korea

4.8.1 South Korea: CMO Revenues 2012-2022

5. Leading Pharmaceutical Contract Manufacturers 2012

5.1 The Pharmaceutical Contract Manufacturing Market by Company in 2011

5.1.1 Significant Deals in 2011 and 2012

5.2 Catalent

5.2.1 Recent Financial Performance

5.2.2 Strong Growth for Oral Delivery Technologies

5.2.3 Catalent Adjusts its Services

5.2.4 Outlook

5.3 Lonza

5.3.1 Recent Financial Performance

5.3.2 Lonza and Biologics

5.3.3 Lonza and Regenerative Medicine

5.3.4 Lonza Expands in Asia and Africa

5.3.5 Outlook

5.4 Boehringer Ingelheim

5.4.1 Recent Financial Performance

5.4.2 Ben Venue Laboratories

5.4.3 Manufacturing Deals 2011-2012

5.4.4 Outlook

5.5 Royal DSM

5.5.1 Recent Financial Performance

5.5.2 DSM Reorganises its Anti-Infectives Division

5.5.3 New Service Offerings

5.5.4 Outlook

5.6 Patheon

5.6.1 Recent Financial Performance

5.6.2 Developed Market Reorganisation

5.6.3 New Services and Focus

5.6.4 Outlook

5.7 Dr. Reddy's Laboratories

5.7.1 Recent Financial Performance

5.7.2 Continued Investment in the UK

5.7.3 Outlook

5.8 Abbott Laboratories

5.8.1 Abbott Laboratories to Split

5.8.2 Outlook

5.9 Jubilant Life Sciences

5.9.1 Recent Financial Performance

5.9.2 Manufacturing Partnerships 2011-2012

5.9.3 Outlook

5.10 Haupt Pharma

5.10.1 Focus on the EU, the US and Japan

5.10.2 Outlook

5.11 Recipharm

5.11.1 Recent Financial Performance

5.11.2 Strategic Acquisitions 2010-2012

5.11.3 Outlook

5.12 Pfizer

5.12.1 Meeting Market Demands

5.13 Piramal Healthcare

5.13.1 Recent Financial Performance

5.13.2 US and EU Expansion

5.13.3 Outlook

5.14 Evonik Degussa

5.14.1 Growing Through Acquisitions

5.14.2 Specialising in HPAPIs

5.15 Aenova

5.15.1 Specialising in Solid Dosage Forms

5.16 Nipro

5.16.1 Recent Financial Performance

5.16.2 Outlook

5.17 Divis Laboratories

5.17.1 Recent Financial Performance

5.17.2 Outlook

5.18 Hospira One 2 One

5.19 Famar

5.19.1 Expansion in Spain

5.20 Fareva

5.20.1 Company and Facility Acquisitions 2011

5.21 Kemwell Biopharma

5.21.1 Biologics and Biosimilars

5.21.2 Facility Growth

6. Pharmaceutical Contract Manufacturing Industry Trends 2012-2022: CMO Perspective

6.1 Pharmaceutical Contract Manufacturing Market: Strengths and Weaknesses for CMOs 2011-2012

6.2 Pharmaceutical Contract Manufacturing Market: Opportunities and Threats for CMOs 2012-2022

6.3 Pharmaceutical Contract Manufacturing Market: STEP Analysis for CMOs 2012-2022

6.4 Trends in Drug Development

6.4.1 Orphan Drug Development

6.4.2 Biologics and Biosimilars

6.4.2.1 Antibody-Drug Conjugates (ADCs)

6.4.2.2 Challenges in Manufacturing Biologics

6.4.2.3 Lyophilisation as a Service

6.4.2.4 The Rise of Biosimilars

6.5 CMO Expansion

6.5.1 An Increasingly Competitive Market

6.5.2 Regional Expansion

6.5.3 Buying Underused Facilities

6.5.3.1 The Risk of Overcapacity

6.5.4 CMOs as a One-Stop-Shop

6.5.5 CMO Consolidation

6.5.6 Manufacturing Clinical Trial Materials

6.5.7 Pharmaceutical Companies as Competitors

6.6 Improving Manufacturing Processes

6.6.1 Quality by Design (QbD)

6.6.2 Batch vs. Continuous Manufacturing

7. Pharmaceutical Contract Manufacturing Industry Trends 2012-2022: Client Perspective

7.1 Pharmaceutical Contract Manufacturing Market: Strengths and Weaknesses for Drug Developers 2011-2012

7.2 Pharmaceutical Contract Manufacturing Market: Opportunities and Threats for Drug Developers 2012-2022

7.3 The Outsourcing Decision

7.3.1 Reasons and Benefits to Outsourcing

7.3.2 Risks in Outsourcing Manufacturing

7.3.3 Selecting a CMO

7.3.4 Globalisation vs. Localisation

7.3.5 Using Emerging Market CMOs

7.3.6 Strategic Partnering

7.4 Outsourcing Strategy Depends on Company Size

7.4.1 Virtual Pharmaceutical Companies

7.5 Good Communication is Vital

7.5.1 Technology Transfer

7.6 Regulatory Compliance

7.6.1 The Responsibility of the Pharmaceutical Client

7.6.1.1 Drug Recalls

8. Regulatory Aspects of Pharmaceutical Manufacturing 2012-2022

8.1 Good Manufacturing Practice (GMP)

8.2 Global Harmonisation of Manufacturing Regulations: The ICH

8.2.1 ICH Q11

8.3 Collaboration Between Regulatory Bodies

8.4 Pharmaceutical Manufacturing Regulation in the US

8.4.1 Response to Industry Trends

8.4.2 The FDA and Foreign Manufacturing Sites

8.4.3 Generic Drug User Fee Act 2012

8.5 European Manufacturing Regulations

8.5.1 API Regulation in the EU

8.5.1.1 Falsified Medicine Directive

8.5.2 Other Recent Regulation Revisions

8.6 Pharmaceutical Manufacturing in Japan

8.7 Emerging Markets and Manufacturing Regulations

8.7.1 Brazil

8.7.2 Russia

8.7.3 India

8.7.4 China

8.7.4.1 Consequences of Stricter Regulations

8.8 South Korea

9. Opinions from Our Survey: Research Interviews

9.1 Dr Franck Latrille, CEO, NextPharma Technologies

9.1.1 NextPharma Technologies

9.1.2 Change in Demand for Contract Manufacturing Services

9.1.3 Opportunities for Growth and Market Restraints

9.1.4 Growth for NextPharma

9.1.5 The Advantages of a Full Service CMO

9.2 Mr Kevin Cook, Managing Director, API Business Unit, Aesica Pharmaceuticals

9.2.1 Aesica Pharmaceuticals

9.2.1.1 Recent Acquisitions

9.2.2 Patent Expiries and the European API Manufacturing Market

9.2.3 Opportunities for European API Manufacturers

9.2.4 The Impact of the Falsified Medicines Directive

9.2.5 Outlook for Aesica Pharmaceuticals

10. Conclusions

10.1 State of the Pharmaceutical Contract Manufacturing Market in 2011

10.2 Growth in the Pharmaceutical Contract Manufacturing Market 2012-2022

10.2.1 The API Manufacturing Market 2012-2022

10.2.2 The Finished Dosage Form Manufacturing Market 2012-2022

10.3 Regional Breakdown of the Pharmaceutical Contract Manufacturing Market 2012-2022

10.3.1 Regional Developments in Supply of Services

10.3.2 Regional Developments in Demand for Services

10.4 Many Opportunities Exist

List of Tables

Table 1.1 Currency Exchange Rates, 2011

Table 3.1 Pharmaceutical Contract Manufacturing Market by Sector, 2011

Table 3.2 Recent Financial Performance for the Five Leading CMOs, Combined, 2009- 2011

Table 3.3 World Biologics Market by Company, 2011

Table 3.4 Pharmaceutical Contract Manufacturing Market: Overall Market and Revenue Forecasts by Sector, 2011-2022

Table 3.5 Pharmaceutical Contract Manufacturing Submarket Shares, 2011-2022

Table 3.6 Pharmaceutical Contract Manufacturing Market: Drivers and Restraints, 2012-2022

Table 3.7 API Contract Manufacturing Submarket by Sector, 2011

Table 3.8 API Contract Manufacturing Submarket: Revenue Forecast, 2011-2022

Table 3.9 API Contract Manufacturing Market: Drivers and Restraints, 2012-2022

Table 3.10 Generic API Contract Manufacturing Submarket: Revenue Forecast, 2011-2022

Table 3.11 HPAPI Contract Manufacturing Submarket: Revenue Forecast, 2011-2022

Table 3.12 Finished Dosage Form Contract Manufacturing Submarket by Sector, 2011

Table 3.13 Finished Dosage Form Contract Manufacturing Submarket: Revenue Forecast, 2011-2022

Table 3.14 Finished Dosage Form Contract Manufacturing Market: Drivers and Restraints, 2012-2022

Table 3.15 Solid Dosage Contract Manufacturing Submarket: Revenue Forecast, 2011-2022

Table 3.16 Injectable Dosage Contract Manufacturing Submarket: Revenue Forecast, 2011-2022

Table 4.1 Pharmaceutical Contract Manufacturing Market by Country, 2011

Table 4.2 Pharmaceutical Contract Manufacturing Market: Revenue Forecasts by Country, 2011-2022

Table 4.3 Pharmaceutical Contract Manufacturing: Market Shares by Country, 2011-2022

Table 4.4 US Submarket: Revenue Forecast, 2011-2022

Table 4.5 Pharmaceutical Contract Manufacturing: EU Market by Country, 2011

Table 4.6 EU Pharmaceutical Contract Manufacturing Market: Revenue Forecasts by Leading Country 2011-2022

Table 4.7 German Submarket: Revenue Forecast, 2011-2022

Table 4.8 French Submarket: Revenue Forecast, 2011-2022

Table 4.9 Italian Submarket: Revenue Forecast, 2011-2022

Table 4.10 Spanish Submarket: Revenue Forecast, 2011-2022

Table 4.11 UK Submarket: Revenue Forecast, 2011-2022

Table 4.12 Japanese Submarket: Revenue Forecast, 2011-2022

Table 4.13 Brazilian Submarket: Revenue Forecast, 2011-2022

Table 4.14 Russian Submarket: Revenue Forecast, 2011-2022

Table 4.15 Indian Submarket: Revenue Forecast, 2011-2022

Table 4.16 Chinese Submarket: Revenue Forecast, 2011-2022

Table 4.17 South Korean Submarket: Revenue Forecast, 2011-2022

Table 5.1 Pharmaceutical Contract Manufacturing Market by Company, 2011

Table 5.2 Selected Manufacturing Deals for Leading CMOs, 2011-2012

Table 5.3 Capacity Expansion for Leading CMOs, 2011-2012

Table 5.4 Catalent: Revenue by Division, 2009-2011

Table 5.5 Lonza: Custom Manufacturing Revenue, 2009-2011

Table 5.6 Boehringer Ingelheim: Contract Manufacturing Revenue by Division, 2009-2011

Table 5.7 DSM: Contract Manufacturing Revenue, 2009-2011

Table 5.8 DSM: Contract Manufacturing Revenue by Division, 2010-2011

Table 5.9 Patheon: Contract Manufacturing Revenue by Division, 2009-2011

Table 5.10 Global DMFs Submitted by Dr. Reddy's Laboratories to 2012

Table 5.11 Dr. Reddy's Laboratories: Contract Manufacturing Revenue, 2010-2012

Table 5.12 Jubilant Life Sciences: Contract Manufacturing Revenue by Division, 2009-2011

Table 5.13 Haupt Pharma: Revenue, 2005-2011

Table 5.14 Recipharm: Revenue by Customer Type, 2011

Table 5.15 Recipharm: Revenue by Region, 2009-2011

Table 5.16 Pfizer: Contract Manufacturing Revenue by Region, 2009-2011

Table 5.17 Piramal Pharma Solutions: Contract Manufacturing Revenue by Region, 2011-2012

Table 5.18 Nipro: Pharmaceutical Business Revenue, 2010-2012

Table 5.19 Divis Laboratories: Contract Manufacturing Revenue by Region, 2011-2012

Table 6.1 Pharmaceutical Contract Manufacturing Market Strengths and Weaknesses: CMO Perspective, 2012

Table 6.2 Pharmaceutical Contract Manufacturing Market Opportunities and Threats: CMO Perspective, 2012-2022

Table 6.3 Pharmaceutical Contract Manufacturing Market: STEP Analysis, 2012-2022

Table 6.4 Selected Pharmaceutical Industry Facility Buyouts, 2011-2012

Table 7.1 Pharmaceutical Contract Manufacturing Market Strengths and Weaknesses: Client Perspective, 2012

Table 7.2 Pharmaceutical Contract Manufacturing Market Opportunities and Threats: Client Perspective, 2012-2022

Table 7.3 Comparison of Selected European and Indian API Manufacturers

Table 8.1 ICH Guidelines: Key Facts and Adoption, 2000-2012

Table 9.1 NextPharma Technologies: Global Locations and Capabilities, 2012

Table 10.1 Pharmaceutical Contract Manufacturing Market: Revenues by Sector, 2011, 2016 and 2022

Table 10.2 Pharmaceutical Contract Manufacturing Market: Revenues by Region, 2011, 2016 and 2022

List of Figures

Figure 2.1 Selected Tasks Outsourced in the Pharmaceutical Industry, 2012

Figure 2.2 The Rise of Contract Development and Manufacturing Organisations

Figure 3.1 Pharmaceutical Contract Manufacturing Market by Sector, 2011

Figure 3.2 Recent Financial Performance for the Five Leading CMOs, Combined, 2009-2011

Figure 3.3 World Biologics Market by Company, 2011

Figure 3.4 Pharmaceutical Contract Manufacturing Market: Overall Market Forecast, 2011-2022

Figure 3.5 Pharmaceutical Contract Manufacturing: Market Shares by Sector, 2016

Figure 3.6 Pharmaceutical Contract Manufacturing: Market Shares by Sector, 2022

Figure 3.7 API Contract Manufacturing Submarket by Sector, 2011

Figure 3.8 API Contract Manufacturing Submarket: Revenue Forecast, 2011-2022

Figure 3.9 Generic API Contract Manufacturing: Submarket Revenue Forecast, 2011-2022

Figure 3.10 HPAPI Contract Manufacturing Submarket: Revenue Forecast, 2011-2022

Figure 3.11 Finished Dosage Form Contract Manufacturing Submarket by Sector, 2011

Figure 3.12 Finished Dosage Form Contract Manufacturing Submarket: Revenue Forecast, 2011-2022

Figure 3.13 Solid Dosage Contract Manufacturing Submarket: Revenue Forecast, 2011-2022

Figure 3.14 Injectable Dosage Contract Manufacturing Submarket: Revenue Forecast, 2011-2022

Figure 4.1 Pharmaceutical Contract Manufacturing: Market Shares by Country, 2011

Figure 4.2 Pharmaceutical Contract Manufacturing: Market Shares by Country, 2016

Figure 4.3 Pharmaceutical Contract Manufacturing: Market Shares by Country, 2022

Figure 4.4 US Submarket: Revenue Forecast, 2011-2022

Figure 4.5 Pharmaceutical Contract Manufacturing: EU Market by Country, 2011

Figure 4.6 EU Submarket: Revenue Forecast, 2011-2022

Figure 4.7 German Submarket: Revenue Forecast, 2011-2022

Figure 4.8 French Submarket: Revenue Forecast, 2011-2022

Figure 4.9 Italian Submarket: Revenue Forecast, 2011-2022

Figure 4.10 Spanish Submarket: Revenue Forecast, 2011-2022

Figure 4.11 UK Submarket: Revenue Forecast, 2011-2022

Figure 4.12 Japanese Submarket: Revenue Forecast, 2011-2022

Figure 4.13 Brazilian Submarket: Revenue Forecast, 2011-2022

Figure 4.14 Russian Submarket: Revenue Forecast, 2011-2022

Figure 4.15 Indian Submarket: Revenue Forecast, 2011-2022

Figure 4.16 Chinese Submarket: Revenue Forecast, 2011-2022

Figure 4.17 South Korean Submarket: Revenue Forecast, 2011-2022

Figure 5.1 Pharmaceutical Contract Manufacturing Market by Company, 2011

Figure 5.2 Catalent: Revenue by Division, 2011

Figure 5.3 Lonza: Custom Manufacturing Revenue, 2009-2011

Figure 5.4 Boehringer Ingelheim: Contract Manufacturing Revenue by Division, 2009-2011

Figure 5.5 DSM: Contract Manufacturing Revenue, 2009-2011

Figure 5.6 Patheon: Contract Manufacturing Revenue by Division, 2009-2011

Figure 5.7 Dr. Reddy's Laboratories: Contract Manufacturing Revenue, 2010-2012

Figure 5.8 Jubilant Life Sciences: Contract Manufacturing Revenue by Division, 2009-2011

Figure 5.9 Haupt Pharma: Revenue, 2005-2011

Figure 5.10 Recipharm: Revenue by Customer Type, 2011

Figure 5.11 Recipharm: Revenue by Region, 2009-2011

Figure 5.12 Pfizer: Contract Manufacturing Revenue by Region, 2009-2011

Figure 5.13 Piramal Pharma Solutions: Contract Manufacturing Revenue by Region, 2011-2012

Figure 5.14 Nipro: Pharmaceutical Business Revenue, 2010-2012

Figure 5.15 Divis Laboratories: Contract Manufacturing Revenue by Region, 2011-2012

Figure 6.1 World Biological Drugs Market Forecast, 2011, 2016 and 2022

Figure 6.2 World Lyophilisation Services and Products: Market Forecasts, 2011, 2016 and 2022

Figure 8.1 Overview of ICH Manufacturing Guidelines, 2012

Figure 9.1 Aesica Pharmaceuticals: Revenue 2010-2011

Figure 10.1 Pharmaceutical Contract Manufacturing Market: Revenues by Sector, 2011, 2016 and 2022

Figure 10.2 Pharmaceutical Contract Manufacturing Market: Revenues by Region, 2011, 2016 and 2022 

Companies Listed

Abbott Contract Manufacturing (part of Abbott Laboratories)

Abbott Laboratories

ADVENTRX Pharmaceuticals

Aenova (formerly Dragenopharm Apotheker Püschl and Swiss Caps)

Aesica Pharmaceuticals

Agência Nacional de Vigilância Sanitária (ANVISA) [Brazil]

Agennix

Albany Molecular Research (AMRI)

Alexion Pharmaceuticals

Amgen

Aptuit

Athera Biotechnologies

Avalanche Biotechnologies

AVEO Pharmaceuticals

Avesthagen

BASF

Ben Venue Laboratories (part of Boehringer Ingelheim)

Bend Research

Biogen Idec

Blackstone Group

Boehringer Ingelheim

Bristol-Myers Squibb

Cambridge Major Laboratories (CML)

Cardinal Health

Catalent

Celltrion

Centocor (now known as Janssen Biologics)

CMIC CMO

Cobra Biologics Holding

Daiichi Sankyo

Department of Pharmaceuticals [India]

Divis Laboratories

Dr. Reddy's Laboratories

DSM Sinochem Pharmaceuticals (DSP)

Eclipse Therapeutics

Elan

Eli Lilly

Emcure Pharmaceuticals

Enobia Pharma (part of Alexion Pharmaceuticals)

European Commission (EC)

European Medicines Agency (EMA)

Evonik Degussa (part of Evonik Industries)

Evonik Industries

Famar

Fareva

Farmhispania

FDA Office of Combination Products (OCP) [US]

Food and Drug Administration (FDA) [US]

Frazier Healthcare

Gallus BioPharmaceuticals

GEA Lyophil

Government Accountability Office (GAO) [US]

GSK

Halo Pharmaceuticals

Haupt Pharma

Hikal

Hospira

Hospira One 2 One (part of Hospira)

Human Genome Sciences (part of GSK)

Immune Pharmaceuticals

Infa Group

International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)

Jubilant HollisterStier (part of Jubilant Life Sciences)

Jubilant Life Sciences

Kemwell Biopharma

Kensey Nash

Korea Food and Drug Administration (KFDA)

Lonza

Marinopoulos Group

Medicines and Healthcare Products Regulatory Agency (MHRA) [UK]

Mesoblast

Ministry of Health, Labor and Welfare (MHLW) [Japan]

MorphoSys

Nascent Biologics

NextPharma Technologies 

Nipro

NKT Therapeutics

Novartis

Nycomed (part of Takeda Pharmaceutical)

Pantec

Patheon

Pfizer

Pfizer CentreSource (part of Pfizer)

Pharmaceutical Research and Manufacturers of America(PhRMA)

Pharmaceuticals and Medical Devices Agency (PMDA) [Japan]

Piramal Healthcare

ProBioGen

Procaps

QRxPharma

Quintiles

R5 (part of Aesica Pharmaceuticals)

Recepta Biopharma

Recipharm

RecipharmCobra Biologics (part of Cobra Biologics Holding)

Roche

Royal DSM

SafeBridge Consultants

Samsung

Samsung BioLogics

Sanofi

SCM Pharma

Seattle Genetics

Sigmar Italia (part of Fareva)

Silverfleet Capital

Sinochem

SkyePharma

State Food and Drug Administration (SFDA) [China]

Sun Capital Partners

SurModics (part of Evonik Industries)

Swedbank

Teva Pharmaceutical Industries

Therapeutic Goods Administration (TGA) [Australia]

UCB

Uquifa

Vetter Pharma-Fertigung

Vivante GMP Solutions (part of Lonza)

Wasserburger Arzneimittelwerk (part of Recipharm)

Wockhardt

World Health Organization (WHO)

Xencor 

To order this report:

Pharmaceutical Industry: Pharmaceutical Contract Manufacturing: World Market Outlook 2012-2022

__________________________

Contact Nicolas: [email protected]

US: (805)-652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker